Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax with Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT03701321Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jan 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax in multiple myeloma (MM) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose up to 35 days and Minimal Residual Disease Negative Status. Planned start Jan 2019; status: withdrawn.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03701321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701321.